HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

MSD concludes Terns acquisition to expand CML pipeline

MSD has completed its acquisition of Terns Pharmaceuticals, expanding its pipeline of treatments for chronic myeloid leukaemia (CML).

By Pharmaceutical Technology · May 6, 2026 · via Pharmaceutical Technology
MSD concludes Terns acquisition to expand CML pipeline

Image: Pharmaceutical Technology

This is an aggregated industry headline. Read the full story at Pharmaceutical Technology →

Tags
dealsformat:headlineheadlinePharmaceutical Technology
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
Madrigal continues MASH deal spree with $1B biobucks license for Arrowhead asset rejected by J&J
DealsFierceBiotech ↗
Madrigal continues MASH deal spree with $1B biobucks license for Arrowhead asset rejected by J&J
Madrigal Pharmaceuticals has struck a backloaded deal for the global license to an Arrowhead Pharmaceuticals p…
May 6, 2026
UCB inks $2B Candid buyout to join Gilead in autoimmune field
DealsFierceBiotech ↗
UCB inks $2B Candid buyout to join Gilead in autoimmune field
UCB has struck a deal to acquire Candid Therapeutics for $2 billion upfront, hijacking a planned reverse merge…
May 5, 2026
UCB bets $2B on Candid's T cell engager ambitions
DealsEndpoints News ↗
UCB bets $2B on Candid's T cell engager ambitions
Ken Song has done it again. The biopharma veteran's all-out effort to prove T cell engagers' potential in auto…
May 4, 2026